Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT06827990

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

Conditions: Aortic Dissection

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 112
Sponsor: W.L.Gore & Associates

Location: University of Alabama at Birmingham Birmingham Alabama

Summary

To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.

Eligibility Criteria

Inclusion Criteria - Primary Arm: The subject is/has: 1. De novo Type A aortic dissection (≤30 days from symptom onset to index endovascular procedure) compatible with the treatment requirements of the ASG device. 2. Primarily intended to be treated by placement of the ASG device in the ascending aorta. Distal adjunctive procedures not in contact with the ASG device may be performed during the index endovascular procedure at the discretion of the Investigator. 3. Anatomic compatibility of the ascending aorta required for implanting the ASG device: a) Proximal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm distal to the most distal coronary artery ostium. ii. Total aortic diameter between 27mm - 48mm iii. Landing zone cannot be heavily calcified or thrombosed. b) Distal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium. c) Adequate aortic length 4. The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria: 1. ≥80 years of age 2. Body mass index (BMI) ≥ 35 kg/m2 3. History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised pulmonary function tests (PFT) on spirometry or other factors as determined by the Investigator) 4. Prior Cardiac Surgery 5. Hostile Chest (VARC-2 Definition) 6. Clinical Frailty Scale 3-7 7. Clinical malperfusion (head, gut, lower extremity) 8. Transfusion is not possible (e.g., Jehovah's Witness) 9. Renal Dialysis prior to aortic dissection 10. Chronic renal insufficiency (eGFR\ 1. Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium. iii. Adequate aortic length 2. Anatomic compatibility required for implanting the ASG device (Intended treatment with ASG device and TBE device) i. Proximal Aortic Landing Zone: 1. Primary entry tear must be identified in Zone 0-5. 2. Landing zone is native aorta. 3. Primary entry tear location is ≥2cm distal to the most distal coronary artery ostium. 4. Proximal landing zone must be ≥2cm in the ascending aorta. 5. Landing zone cannot be heavily calcified or thrombosed. 6. Total aortic landing zone diameter 27mm - 48mm. ii. Branch Vessel Landing Zone: 1. Length of ≥2.5 cm proximal to first major branch vessel. 2. Target branch vessel inner diameters of 11-18 mm. 3. Target branch vessel landing zone must be in native vessel that cannot be heavily calcified or thrombosed. 4. The distal 15mm landing zone cannot be dissected. 4. The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria: 1. ≥80 years of age 2. BMI ≥ 35 kg/m2 3. History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised PFTs on spirometry or other factors as determined by the Investigator) 4. Prior Cardiac Surgery 5. Hostile Chest (VARC-2 Definition) 6. Clinical Frailty Scale 3-9 7. Clinical malperfusion (head, gut, lower extremity) 8. Transfusion is not possible (e.g., Jehovah's Witness) 9. Renal Dialysis prior to aortic dissection 10. Chronic renal insufficiency (eGFR\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06827990). StuddyBuddy aggregates publicly available trial information.